CRISPR Therapeutics AG (FRA:1CG) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1CG CRISPR Therapeutics AG FRA:1CG
41 GF Score
Price €43.03
GF Value €3.08
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

CRISPR Therapeutics AG Valuation Rank Related Terms

FRA:1CG
41GF Score
CRISPR Therapeutics AG FRA:1CG
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CRISPR Therapeutics AG (FRA:1CG) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of €43.03 is trading 1296.9% above its estimated GF Value™ of €3.08. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for FRA:1CG:

  • Valuation Rank:
  • GF Value™: €3.08 vs. price of €43.03 (1296.9% above fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the FRA:1CG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score

Get the complete analysis for FRA:1CG

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.03
Price
€3.08
GF Value